Bristol-Myers Squibb Co. under the ticker symbol BMY. Here is some more information that we have about Bristol-Myers Squibb Co.

Get our alerts and future stock picks in your email inbox

Bristol-Myers Squibb Co.


Bristol-Myers Squibb Company (BMS) engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of pharmaceuticals and nutritional products worldwide. It operates in two segments, Pharmaceuticals and Nutritionals. The Pharmaceuticals segment offers cardiovascular products, including PLAVIX, AVAPRO/AVALIDE, and PRAVACHOL; virology products comprising REYATAZ, SUSTIVA, and BARACLUDE; oncology products comprising ERBITUX, TAXOL, SPRYCEL, and IXEMPRA; affective and other psychiatric disorder products, such as ABILIFY; immunoscience products comprising ORENCIA; and other pharmaceutical products that include EFFERALGAN, ASPIRINE UPSA, DAFALGAN, and FERVEX. It sells its pharmaceutical products to wholesalers, distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The Nutritionals segment manufactures, markets, distributes, and sells infant formulas and other nutritional products comprising ENFAMIL products that contain nutrients, such as docosahexaenoic and arachidonic acids. The company is also developing various compounds, which are in phase III clinical trials, including Apixaban, Saxagliptin, Dapagliflozin, Ipilimumab, Belatacept, XL-184, Tanespimycin, and Brivanib. In addition, it develops a therapeutic class of biologics called ADNECTINS. BMS has agreements with Sanofi-Aventis; Otsuka Pharmaceutical Co., Ltd.; ImClone Systems Incorporated; Gilead Sciences, Inc.; Medarex, Inc.; and AstraZeneca PLC, as well as collaborations with Pfizer Inc.; Exelixis, Inc.; and KineMed Inc. It also has an agreement with PDL BioPharma, Inc. for the development and commercialization of anti-CS1 antibody and elotuzumab for multiple myeloma; and a strategic alliance with Ensemble Discovery Corporation. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
25,000 Employees
Last Reported Date: 02/13/15
Founded in 1887
Last $59.47 USD
Change Today -1.14 / -1.88%
Volume 5.7M
As of 8:04 PM 08/31/15 All times are local (Market data is delayed by at least 15 minutes).

bristol-myers squibb co (BMY) Snapshot

Open
$60.64
Previous Close
$60.61
Day High
$60.99
Day Low
$59.28
52 Week High
07/20/15 - $70.54
52 Week Low
10/15/14 - $47.55
Market Cap
99.2B
Average Volume 10 Days
7.8M
EPS TTM
$1.67
Shares Outstanding
1.7B
EX-Date
07/1/15
P/E TM
35.5x
Dividend
$1.48
Dividend Yield
2.47%
BMY:US Advanced Stock Chart

bristol-myers squibb co (BMY) Related Bloomberg News

AstraZeneca, Bristol-Myers Squibb: Intellectual Property
Bristol-Myers 2015 Sales Forecast Hit by Dollar’s Strength
Stronger Dollar Punishes U.S. Earnings From P&G to DuPont
Fed, U.S. GDP, Greece, Apple, Amazon: Week Ahead Jan. 24-31
Fed, U.S. GDP, Greek Vote, Apple, Amazon: Week Ahead Jan. 24-31

bristol-myers squibb co (BMY) Related News

Company News: Alstom, GE, American Apparel, Bristol-Myers Squibb, Airbus, Starbucks, Square
Prudential Piles on the Corporate Pensions
White-Collar Workers Live Longer and the Gap Is Widening
What's the Dollar Value of Online Patient Chatter?

bristol-myers squibb co (BMY) Key Developments

Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute sign Worldwide Collaboration to Discover Novel Immuno-Oncology Antibodies

Bristol-Myers Squibb Company and QIMR Berghofer Medical Research Institute have signed a research collaboration and license agreement to discover novel therapeutic antibodies against an undisclosed immuno-oncology (I-O) target. QIMR Berghofer Medical Research Institute is a translational research institute focused on cancer, infectious diseases, mental health and a range of complex disorders. Bristol-Myers Squibb will be solely responsible for clinical development and commercialization of antibodies discovered through the collaboration.

Bristol-Myers Squibb Promotes Betty Edery to the Post of General Counsel for France

Bristol-Myers Squibb has promoted Betty Edery to the post of general counsel for France, just over a year after making its last local head of legal appointment. Edery, who was formerly senior legal counsel for Bristol-Myers Squibb France, takes over from Alexandra de Rambuteau as general counsel and a member of the executive committee. De Rambuteau was appointed as general counsel in June last year. It is not known why she is leaving the company or where her next destination is. Edery joined Bristol-Myers Squibb in January 2013, having previously worked for Hogan Lovells in Paris for seven years as a corporate and regulatory lawyer specialising in the pharmaceutical sector.

FDA Approves U.S. Product Labeling Update for Sprycel® (dasatinib)

Bristol-Myers Squibb Company and Otsuka America Pharmaceutical, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved an update to the Sprycel® (dasatinib) product labeling. The labeling now includes five-year efficacy and safety data in adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP) and seven-year data in CP Ph+ CML patients who are resistant1 or intolerant2 to prior therapy, including Gleevec®3 (imatinib mesylate). Sprycel is associated with the following warnings and precautions: myelosuppression, bleeding-related events, fluid retention, cardiovascular events, pulmonary arterial hypertension, QT prolongation, severe dermatologic reactions, tumor lysis syndrome, and embryo-fetal toxicity.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMY:US $59.47 USD -1.14

BMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $62.41 USD -1.57
Allergan plc $303.74 USD -4.27
Eli Lilly & Co $82.35 USD -0.84
Medtronic PLC $72.29 USD -1.27
Novo Nordisk A/S kr363.30 DKK -5.90
 

Industry Analysis

BMY

Industry Average

Valuation BMY Industry Range
Price/Earnings 56.7x
Price/Sales 6.2x
Price/Book 6.7x
Price/Cash Flow 56.5x
TEV/Sales 5.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Credit Suisse's 8 Pharmaceutical Stocks with 'Significant' Upside
  Read More...
Bristol-Myers Squibb's success in Tampa was a major draw for Johnson & Johnson
  Read More...
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
[Business Wire] - Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds and Bristol-Myers Squibb Company , announced that it has entered into a worldwide licensing agreement with Yale University for a proprietary platform technology and associated lead molecules that will be further developed to treat diseases such as prostate cancer, a leading cause of cancer-related deaths ...
  Read More...
Bristol-Myers Squibb
  Read More...
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis
[at noodls] - Twenty-two abstracts to be presented, including new analyses from ARISTOTLE and real-world data analyses evaluating the risk of major bleeding, bleeding-related hospital readmissions, hospitalization rates ...
  Read More...
Piper Jaffray Upgrades Bristol-Myers Squibb, Sees Valuation As Fair
  Read More...
Bristol-Myers upgraded by Piper Jaffray
  Read More...
Broken companies vs. broken stocks
  Read More...
New Skin Cancer Drugs Delayed
  Read More...
Bristol-Myers Strong Reliance On New Drugs Growth: Is It A Huge Risk?
  Read More...
U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo
[at noodls] - August 18, 2015 U.S. Food and Drug Administration Extends Action Date for Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Untreated Advanced Melanoma (PRINCETON, NJ, August ...
  Read More...